Schizophrenia Market Report and Forecast 2025-2034
Description
The schizophrenia market attained a value of USD 7.78 Billion in 2024. The market is further expected to grow in the forecast period of 2025-2034 at a CAGR of 5.80%, to reach USD 13.67 Billion by 2034.
Schizophrenia Market Overview
Schizophrenia is a psychological disorder that describes a series of abnormalities in behavior, thinking, emotional response, and social interaction. It requires a range of therapeutic interventions, such as antipsychotics and psychosocial treatments, to enhance the standard of living. Time and appropriate management strategies are critical if better results are to be obtained. This has resulted in mergers and acquisitions among key players in the market to satisfy the increasing needs of the population for new therapeutic agents.
Schizophrenia Market Growth Drivers
Rising Prevalence of Schizophrenia Drive the Market in the Forecast Period
Schizophrenia is one of the ten leading causes of life disability, and it occurs in approximately 1% of the world population. This has led to a higher expectation of better treatments and health care services. Both the pharmaceutical industry and healthcare providers are now focusing their efforts on the development of better ways of managing symptoms as well as enhancing the quality of the lives of patients.
Schizophrenia Market Trends
Expansion of Long-Acting Injectable Antipsychotics (LAIs)
There has been an increase in the use of long-acting injectable forms of antipsychotic medication among schizophrenia patients. LAIs possess benefits like fewer relapse frequencies and increased comfort as compared to daily oral medications. LAI manufacturers and pharmaceutical companies have sought the introduction of many variations of LAI to satisfy patient demands and meet clinical requirements.
Emerging Therapies in Schizophrenia Treatment
Higher levels of expenditure in research and development for the drug and stronger comprehension of the disease are contributing to the enhancement of clinicians’ information bases. Subsequent research has resulted in indications of possible treatments that are intended to fulfill the unmet needs. Novel products such as Sumitomo Pharma/Otsuka Pharmaceuticals’ Ulotaront (SEP-363856 ) and others are expected to be launched during the forecast period, indicating new entrants in the treatment scenario.
Advancements in Genetic Research
Modern genetic discoveries are influencing the comprehension and management of schizophrenia. Cytogenetic, molecular, and genetic analyses have revealed possible genetic predisposing loci and pathways in cases of the disorder through genome-wide association studies (GWAS) and genetic profiling. This knowledge is fueling the advancement of molecular therapies and individualized medication, to enhance treatment outcomes as well as decrease side effects.
Rise of Digital Therapeutics
The availability of digital therapeutics is increasingly adding to the treatment of schizophrenia. These technologies provide individualized programs, which can include cognitive behavioral therapy (CBT), social skills training, and/or medication management. These tools supplement other conventional treatments and provide patients with more therapeutic assets available at any time. It also helps in improving treatment rates and results by monitoring the patient’s condition and analyzing data remotely.
Recent Developments in Schizophrenia Market
In December 2023, Bristol Myers Squibb (BMS) acquired Karuna Therapeutics for USD 14 billion to strengthen its neuroscience division. The acquisition focuses on the development of KarXT, a novel M1/M4 muscarinic receptor agonist, for the treatment of schizophrenia and Alzheimer’s disease psychosis. The drug is planned to be introduced into the United States market in late 2024 for the treatment of schizophrenia in adults.
In January 2023, Newron Pharmaceuticals S.p.A provided six-month interim data from a clinical trial conducted in Italy concerning the use of evenamide as an add-on treatment option for schizophrenia patients who failed to respond to first-line antipsychotics. The trial involved 100 patients, and all of them noticed improvements in the symptoms of treatment-resistant schizophrenia (TRS) after the six-month trial and a doubling of improved conditions in comparison with the outcome of the six-week trial. This was assessed using the Positive and Negative Syndrome Scale (PANNS) and Clinical Global Impression of Severity (CGI-S), which also revealed positive, statistically significant improvements. The therapy was side-effect-free and was an important sign of a better approach to TRS.
Schizophrenia Market Segmentation
Schizophrenia Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
The Oral Route is Anticipated to Have the Largest Market Share Based on the Route of Administration
Based on the route of administration, the schizophrenia market is divided into oral, parenteral, and others. The oral route is expected to dominate the market because of its better patient acceptance. They are easier to take than injectable medicines and, hence, promote patient compliance.
Males Lead the Market Share Based on Gender
Based on gender, the schizophrenia market is divided into male and female, with the male segment leading due to a higher prevalence of schizophrenia in males compared to females. This gender difference affects the present market scenario for schizophrenia by promoting the need for therapeutic strategies. The pharmaceutical industry and healthcare sectors are targeting men’s health in research to enhance health solutions with the view of providing better treatments for this specific audience.
Schizophrenia Market Analysis by Region
Based on regional segmentation, the schizophrenia market is categorized into key regions including the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. Among these, the United States holds the largest market share because of factors including a high percentage of healthcare spending, advanced healthcare systems, a high level of investment in research and development, and a comparatively higher incidence of schizophrenia than other parts of the world. The well-developed pharmaceutical industry in the United States concentrates on the creation of new products for schizophrenia treatment. This dominance affects the present market situation in various ways, such as by affecting global treatment protocols, clinical research, and the incorporation of new therapeutic regimes.
Leading Players in the Schizophrenia Market
The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Bristol-Myers Squibb Company
Founded in 1887 and based in New York, United States, the company provides schizophrenia medications including Abilify Maintena used for maintenance treatment and the Otsuka collaboration products including Rexulti employed to handle several parameters of schizophrenia.
AstraZeneca PLC
This England-based pharma company, founded in 1999, offers drugs including Seroquel (quetiapine) which is prescribed for schizophrenia and bipolar disorder with the intent to mitigate manifesting symptoms and enhance the patient’s quality of life.
Eli Lilly And Company
An American company, established in 1876, it is involved in the treatment of schizophrenia through drugs including Zyprexa(olanzapine), aimed at controlling certain aspects of the disease.
Sumitomo Pharma Co Ltd
It is a Japanese pharmaceutical company founded in 1897. It contributes to schizophrenia treatment with products such as Risperdal, which is applied for stabilizing schizophrenic symptoms and enhancing the functional status of the patients.
Other companies include Johnson & Johnson Services, Inc., Pfizer, Inc., Vanda Pharmaceuticals, Allergan, Inc., H. Lundbeck A/S, Alkermes plc, AbbVie Inc., Acadia Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Reviva Pharmaceuticals Holdings, Inc., and Newron Pharmaceuticals Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been in the report.
Key Questions Answered in the Schizophrenia Market
Schizophrenia Market Overview
Schizophrenia is a psychological disorder that describes a series of abnormalities in behavior, thinking, emotional response, and social interaction. It requires a range of therapeutic interventions, such as antipsychotics and psychosocial treatments, to enhance the standard of living. Time and appropriate management strategies are critical if better results are to be obtained. This has resulted in mergers and acquisitions among key players in the market to satisfy the increasing needs of the population for new therapeutic agents.
Schizophrenia Market Growth Drivers
Rising Prevalence of Schizophrenia Drive the Market in the Forecast Period
Schizophrenia is one of the ten leading causes of life disability, and it occurs in approximately 1% of the world population. This has led to a higher expectation of better treatments and health care services. Both the pharmaceutical industry and healthcare providers are now focusing their efforts on the development of better ways of managing symptoms as well as enhancing the quality of the lives of patients.
Schizophrenia Market Trends
Expansion of Long-Acting Injectable Antipsychotics (LAIs)
There has been an increase in the use of long-acting injectable forms of antipsychotic medication among schizophrenia patients. LAIs possess benefits like fewer relapse frequencies and increased comfort as compared to daily oral medications. LAI manufacturers and pharmaceutical companies have sought the introduction of many variations of LAI to satisfy patient demands and meet clinical requirements.
Emerging Therapies in Schizophrenia Treatment
Higher levels of expenditure in research and development for the drug and stronger comprehension of the disease are contributing to the enhancement of clinicians’ information bases. Subsequent research has resulted in indications of possible treatments that are intended to fulfill the unmet needs. Novel products such as Sumitomo Pharma/Otsuka Pharmaceuticals’ Ulotaront (SEP-363856 ) and others are expected to be launched during the forecast period, indicating new entrants in the treatment scenario.
Advancements in Genetic Research
Modern genetic discoveries are influencing the comprehension and management of schizophrenia. Cytogenetic, molecular, and genetic analyses have revealed possible genetic predisposing loci and pathways in cases of the disorder through genome-wide association studies (GWAS) and genetic profiling. This knowledge is fueling the advancement of molecular therapies and individualized medication, to enhance treatment outcomes as well as decrease side effects.
Rise of Digital Therapeutics
The availability of digital therapeutics is increasingly adding to the treatment of schizophrenia. These technologies provide individualized programs, which can include cognitive behavioral therapy (CBT), social skills training, and/or medication management. These tools supplement other conventional treatments and provide patients with more therapeutic assets available at any time. It also helps in improving treatment rates and results by monitoring the patient’s condition and analyzing data remotely.
Recent Developments in Schizophrenia Market
In December 2023, Bristol Myers Squibb (BMS) acquired Karuna Therapeutics for USD 14 billion to strengthen its neuroscience division. The acquisition focuses on the development of KarXT, a novel M1/M4 muscarinic receptor agonist, for the treatment of schizophrenia and Alzheimer’s disease psychosis. The drug is planned to be introduced into the United States market in late 2024 for the treatment of schizophrenia in adults.
In January 2023, Newron Pharmaceuticals S.p.A provided six-month interim data from a clinical trial conducted in Italy concerning the use of evenamide as an add-on treatment option for schizophrenia patients who failed to respond to first-line antipsychotics. The trial involved 100 patients, and all of them noticed improvements in the symptoms of treatment-resistant schizophrenia (TRS) after the six-month trial and a doubling of improved conditions in comparison with the outcome of the six-week trial. This was assessed using the Positive and Negative Syndrome Scale (PANNS) and Clinical Global Impression of Severity (CGI-S), which also revealed positive, statistically significant improvements. The therapy was side-effect-free and was an important sign of a better approach to TRS.
Schizophrenia Market Segmentation
Schizophrenia Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Paranoid Schizophrenia
- Hebephrenic Schizophrenia
- Catatonic Schizophrenia
- Undifferentiated Schizophrenia
- First Generation Antipsychotics
- Chlorpromazine
- Fluphenazine
- Haloperidol
- Perphenazine
- Others
- Second Generation Antipsychotics
- Aripiprazole
- Cariprazine
- Brexpiprazole
- Aripiprazole Lauroxil
- Others
- Others
- Oral
- Parenteral
- Others
- Male
- Female
- Retail Pharmacies
- Hospital Pharmacies
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
The Oral Route is Anticipated to Have the Largest Market Share Based on the Route of Administration
Based on the route of administration, the schizophrenia market is divided into oral, parenteral, and others. The oral route is expected to dominate the market because of its better patient acceptance. They are easier to take than injectable medicines and, hence, promote patient compliance.
Males Lead the Market Share Based on Gender
Based on gender, the schizophrenia market is divided into male and female, with the male segment leading due to a higher prevalence of schizophrenia in males compared to females. This gender difference affects the present market scenario for schizophrenia by promoting the need for therapeutic strategies. The pharmaceutical industry and healthcare sectors are targeting men’s health in research to enhance health solutions with the view of providing better treatments for this specific audience.
Schizophrenia Market Analysis by Region
Based on regional segmentation, the schizophrenia market is categorized into key regions including the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. Among these, the United States holds the largest market share because of factors including a high percentage of healthcare spending, advanced healthcare systems, a high level of investment in research and development, and a comparatively higher incidence of schizophrenia than other parts of the world. The well-developed pharmaceutical industry in the United States concentrates on the creation of new products for schizophrenia treatment. This dominance affects the present market situation in various ways, such as by affecting global treatment protocols, clinical research, and the incorporation of new therapeutic regimes.
Leading Players in the Schizophrenia Market
The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Bristol-Myers Squibb Company
Founded in 1887 and based in New York, United States, the company provides schizophrenia medications including Abilify Maintena used for maintenance treatment and the Otsuka collaboration products including Rexulti employed to handle several parameters of schizophrenia.
AstraZeneca PLC
This England-based pharma company, founded in 1999, offers drugs including Seroquel (quetiapine) which is prescribed for schizophrenia and bipolar disorder with the intent to mitigate manifesting symptoms and enhance the patient’s quality of life.
Eli Lilly And Company
An American company, established in 1876, it is involved in the treatment of schizophrenia through drugs including Zyprexa(olanzapine), aimed at controlling certain aspects of the disease.
Sumitomo Pharma Co Ltd
It is a Japanese pharmaceutical company founded in 1897. It contributes to schizophrenia treatment with products such as Risperdal, which is applied for stabilizing schizophrenic symptoms and enhancing the functional status of the patients.
Other companies include Johnson & Johnson Services, Inc., Pfizer, Inc., Vanda Pharmaceuticals, Allergan, Inc., H. Lundbeck A/S, Alkermes plc, AbbVie Inc., Acadia Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Reviva Pharmaceuticals Holdings, Inc., and Newron Pharmaceuticals Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been in the report.
Key Questions Answered in the Schizophrenia Market
- What was the schizophrenia market value in 2023?
- What is the schizophrenia market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What are the major factors aiding the schizophrenia market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major schizophrenia market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the schizophrenia market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- What is the market segmentation based on type?
- What is the market breakdown based on drug class?
- What is the market segmentation based on the route of administration?
- Which route of administration (oral, parenteral, others) is preferred by patients and why?
- What is the market breakup based on gender?
- What is the incidence rate of schizophrenia in males versus females, and how does it impact market strategies?
- What is the market breakup based on the distribution channel?
- Which region is expected to lead the schizophrenia market, and what are the contributing factors
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Schizophrenia Market Overview: 8 Major Markets
- 3.1 Schizophrenia Market Historical Value (2018-2024)
- 3.2 Schizophrenia Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Schizophrenia: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Schizophrenia Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.3.1 Germany
- 7.1.1.3.2 France
- 7.1.1.3.3 Italy
- 7.1.1.3.4 Spain
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.3.1 Germany
- 7.1.2.3.2 France
- 7.1.2.3.3 Italy
- 7.1.2.3.4 Spain
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.3.1 Germany
- 7.1.3.3.2 France
- 7.1.3.3.3 Italy
- 7.1.3.3.4 Spain
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Schizophrenia Market Landscape: 8 Major Markets*
- 8.1 Schizophrenia Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Schizophrenia Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Drug Class
- 8.2.3 Analysis by Route of Administration
- 9 Schizophrenia Market Therapy Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 8MM Schizophrenia Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Schizophrenia Market Segmentation: 8 Major Markets
- 12.1 Schizophrenia Market by Type
- 12.1.1 Market Overview
- 12.1.2 Paranoid Schizophrenia
- 12.1.3 Hebephrenic Schizophrenia
- 12.1.4 Catatonic Schizophrenia
- 12.1.5 Undifferentiated Schizophrenia
- 12.2 Schizophrenia Market by Drug Class
- 12.2.1 Market Overview
- 12.2.2 First Generation Antipsychotics
- 12.2.2.1 Chlorpromazine
- 12.2.2.2 Fluphenazine
- 12.2.2.3 Haloperidol
- 12.2.2.4 Perphenazine
- 12.2.2.5 Others
- 12.2.3 Second Generation Antipsychotics
- 12.2.3.1 Aripiprazole
- 12.2.3.2 Cariprazine
- 12.2.3.3 Brexpiprazole
- 12.2.3.4 Aripiprazole Lauroxil
- 12.2.3.5 Others
- 12.2.4 Others
- 12.3 Schizophrenia Market by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Parenteral
- 12.3.4 Others
- 12.4 Schizophrenia Market by Gender
- 12.4.1 Market Overview
- 12.4.2 Male
- 12.4.3 Female
- 12.5 Schizophrenia Market by Distribution Channel
- 12.5.1 Market Overview
- 12.5.2 Retail Pharmacies
- 12.5.3 Hospital Pharmacies
- 12.5.4 Others
- 12.6 Schizophrenia Market by Region
- 12.6.1 Market Overview
- 12.6.2 United States
- 12.6.3 EU-4 and the United Kingdom
- 12.6.3.1 Germany
- 12.6.3.2 France
- 12.6.3.3 Italy
- 12.6.3.4 Spain
- 12.6.3.5 United Kingdom
- 12.6.4 Japan
- 12.6.5 India
- 13 United States Schizophrenia Market (218-2034)
- 13.1 United States Schizophrenia Market Historical Value (2018-2024)
- 13.2 United States Schizophrenia Market Forecast Value (2025-2034)
- 13.3 United States Schizophrenia Market by Type
- 13.3.1 Market Overview
- 13.3.2 Paranoid Schizophrenia
- 13.3.3 Hebephrenic Schizophrenia
- 13.3.4 Catatonic Schizophrenia
- 13.3.5 Undifferentiated Schizophrenia
- 13.4 United States Schizophrenia Market by Drug Class
- 13.4.1 Market Overview
- 13.4.2 First Generation Antipsychotics
- 13.4.2.1 Chlorpromazine
- 13.4.2.2 Fluphenazine
- 13.4.2.3 Haloperidol
- 13.4.2.4 Perphenazine
- 13.4.2.5 Others
- 13.4.3 Second Generation Antipsychotics
- 13.4.3.1 Aripiprazole
- 13.4.3.2 Cariprazine
- 13.4.3.3 Brexpiprazole
- 13.4.3.4 Aripiprazole Lauroxil
- 13.4.3.5 Others
- 13.4.4 Others
- 13.5 United States Schizophrenia Market by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Oral
- 13.5.3 Parenteral
- 13.6 United States Schizophrenia Market by Gender
- 13.6.1 Market Overview
- 13.6.2 Male
- 13.6.3 Female
- 13.7 United States Schizophrenia Market by Distribution Channel
- 13.7.1 Market Overview
- 13.7.2 Retail Pharmacies
- 13.7.3 Hospital Pharmacies
- 13.7.4 Others
- 14 EU-4 and United Kingdom Schizophrenia Market (218-2034)
- 14.1 EU-4 and United Kingdom Schizophrenia Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Schizophrenia Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Schizophrenia Market by Type
- 14.3.1 Market Overview
- 14.3.2 Paranoid Schizophrenia
- 14.3.3 Hebephrenic Schizophrenia
- 14.3.4 Catatonic Schizophrenia
- 14.3.5 Undifferentiated Schizophrenia
- 14.4 EU-4 and United Kingdom Schizophrenia Market by Drug Class
- 14.4.1 Market Overview
- 14.4.2 First Generation Antipsychotics
- 14.4.2.1 Chlorpromazine
- 14.4.2.2 Fluphenazine
- 14.4.2.3 Haloperidol
- 14.4.2.4 Perphenazine
- 14.4.2.5 Others
- 14.4.3 Second Generation Antipsychotics
- 14.4.3.1 Aripiprazole
- 14.4.3.2 Cariprazine
- 14.4.3.3 Brexpiprazole
- 14.4.3.4 Aripiprazole Lauroxil
- 14.4.3.5 Others
- 14.4.4 Others
- 14.5 EU-4 and United Kingdom Schizophrenia Market by Route of Administration
- 14.5.1 Market Overview
- 14.5.2 Oral
- 14.5.3 Parenteral
- 14.6 EU-4 and United Kingdom Schizophrenia Market by Gender
- 14.6.1 Market Overview
- 14.6.2 Male
- 14.6.3 Female
- 14.7 EU-4 and United Kingdom Schizophrenia Market by Distribution Channel
- 14.7.1 Market Overview
- 14.7.2 Retail Pharmacies
- 14.7.3 Hospital Pharmacies
- 14.7.4 Others
- 15 Japan Schizophrenia Market
- 15.1 Japan Schizophrenia Market Historical Value (2018-2024)
- 15.2 Japan Schizophrenia Market Forecast Value (2025-2034)
- 15.3 Japan Schizophrenia Market by Type
- 15.3.1 Market Overview
- 15.3.2 Paranoid Schizophrenia
- 15.3.3 Hebephrenic Schizophrenia
- 15.3.4 Catatonic Schizophrenia
- 15.3.5 Undifferentiated Schizophrenia
- 15.4 Japan Schizophrenia Market by Drug Class
- 15.4.1 Market Overview
- 15.4.2 First Generation Antipsychotics
- 15.4.2.1 Chlorpromazine
- 15.4.2.2 Fluphenazine
- 15.4.2.3 Haloperidol
- 15.4.2.4 Perphenazine
- 15.4.2.5 Others
- 15.4.3 Second Generation Antipsychotics
- 15.4.3.1 Aripiprazole
- 15.4.3.2 Cariprazine
- 15.4.3.3 Brexpiprazole
- 15.4.3.4 Aripiprazole Lauroxil
- 15.4.3.5 Others
- 15.4.4 Others
- 15.5 Japan Schizophrenia Market by Route of Administration
- 15.5.1 Market Overview
- 15.5.2 Oral
- 15.5.3 Parenteral
- 15.6 Japan Schizophrenia Market by Gender
- 15.6.1 Market Overview
- 15.6.2 Male
- 15.6.3 Female
- 15.7 Japan Schizophrenia Market by Distribution Channel
- 15.7.1 Market Overview
- 15.7.2 Retail Pharmacies
- 15.7.3 Hospital Pharmacies
- 15.7.4 Others
- 16 India Schizophrenia Market
- 16.1 India Schizophrenia Market (2018-2034) Historical Value (2018-2024)
- 16.2 India Schizophrenia Market (2018-2034) Forecast Value (2025-2034)
- 16.3 India Schizophrenia Market by Type
- 16.3.1 Market Overview
- 16.3.2 Paranoid Schizophrenia
- 16.3.3 Hebephrenic Schizophrenia
- 16.3.4 Catatonic Schizophrenia
- 16.3.5 Undifferentiated Schizophrenia
- 16.4 India Schizophrenia Market by Drug Class
- 16.4.1 Market Overview
- 16.4.2 First Generation Antipsychotics
- 16.4.2.1 Chlorpromazine
- 16.4.2.2 Fluphenazine
- 16.4.2.3 Haloperidol
- 16.4.2.4 Perphenazine
- 16.4.2.5 Others
- 16.4.3 Second Generation Antipsychotics
- 16.4.3.1 Aripiprazole
- 16.4.3.2 Cariprazine
- 16.4.3.3 Brexpiprazole
- 16.4.3.4 Aripiprazole Lauroxil
- 16.4.3.5 Others
- 16.4.4 Others
- 16.5 India Schizophrenia Market by Route of Administration
- 16.5.1 Market Overview
- 16.5.2 Oral
- 16.5.3 Parenteral
- 16.6 India Schizophrenia Market by Gender
- 16.6.1 Market Overview
- 16.6.2 Male
- 16.6.3 Female
- 16.7 India Schizophrenia Market by Distribution Channel
- 16.7.1 Market Overview
- 16.7.2 Retail Pharmacies
- 16.7.3 Hospital Pharmacies
- 16.7.4 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Strategic Initiatives
- 21.1 Analysis by Partnership Instances
- 21.2 Analysis by Type of Partnership
- 21.3 Analysis by Leading Players
- 21.4 Analysis by Geography
- 22 Supplier Landscape
- 22.1 Market Share by Top 5 Companies
- 22.2 Johnson & Johnson Services, Inc.
- 22.2.1 Financial Analysis
- 22.2.2 Product Portfolio
- 22.2.3 Demographic Reach and Achievements
- 22.2.4 Mergers and Acquisitions
- 22.2.5 Certifications
- 22.3 Bristol-Myers Squibb Company
- 22.3.1 Financial Analysis
- 22.3.2 Product Portfolio
- 22.3.3 Demographic Reach and Achievements
- 22.3.4 Mergers and Acquisitions
- 22.3.5 Certifications
- 22.4 AstraZeneca PLC
- 22.4.1 Financial Analysis
- 22.4.2 Product Portfolio
- 22.4.3 Demographic Reach and Achievements
- 22.4.4 Mergers and Acquisitions
- 22.4.5 Certifications
- 22.5 Eli Lilly And Company
- 22.5.1 Financial Analysis
- 22.5.2 Product Portfolio
- 22.5.3 Demographic Reach and Achievements
- 22.5.4 Mergers and Acquisitions
- 22.5.5 Certifications
- 22.6 Sumitomo Pharma Co Ltd
- 22.6.1 Financial Analysis
- 22.6.2 Product Portfolio
- 22.6.3 Demographic Reach and Achievements
- 22.6.4 Mergers and Acquisitions
- 22.6.5 Certifications
- 22.7 Pfizer, Inc.
- 22.7.1 Financial Analysis
- 22.7.2 Product Portfolio
- 22.7.3 Demographic Reach and Achievements
- 22.7.4 Mergers and Acquisitions
- 22.7.5 Certifications
- 22.8 Vanda Pharmaceuticals
- 22.8.1 Financial Analysis
- 22.8.2 Product Portfolio
- 22.8.3 Demographic Reach and Achievements
- 22.8.4 Mergers and Acquisitions
- 22.8.5 Certifications
- 22.9 Allergan, Inc.
- 22.9.1 Financial Analysis
- 22.9.2 Product Portfolio
- 22.9.3 Demographic Reach and Achievements
- 22.9.4 Mergers and Acquisitions
- 22.9.5 Certifications
- 22.10 H. Lundbeck A/S
- 22.10.1 Financial Analysis
- 22.10.2 Product Portfolio
- 22.10.3 Demographic Reach and Achievements
- 22.10.4 Mergers and Acquisitions
- 22.10.5 Certifications
- 22.11 Alkermes plc
- 22.11.1 Financial Analysis
- 22.11.2 Product Portfolio
- 22.11.3 Demographic Reach and Achievements
- 22.11.4 Mergers and Acquisitions
- 22.11.5 Certifications
- 22.12 AbbVie Inc.
- 22.12.1 Financial Analysis
- 22.12.2 Product Portfolio
- 22.12.3 Demographic Reach and Achievements
- 22.12.4 Mergers and Acquisitions
- 22.12.5 Certifications
- 22.13 Acadia Pharmaceuticals Inc.
- 22.13.1 Financial Analysis
- 22.13.2 Product Portfolio
- 22.13.3 Demographic Reach and Achievements
- 22.13.4 Mergers and Acquisitions
- 22.13.5 Certifications
- 22.14 Boehringer Ingelheim International GmbH
- 22.14.1 Financial Analysis
- 22.14.2 Product Portfolio
- 22.14.3 Demographic Reach and Achievements
- 22.14.4 Mergers and Acquisitions
- 22.14.5 Certifications
- 22.15 Reviva Pharmaceuticals Holdings, Inc.
- 22.15.1 Financial Analysis
- 22.15.2 Product Portfolio
- 22.15.3 Demographic Reach and Achievements
- 22.15.4 Mergers and Acquisitions
- 22.15.5 Certifications
- 22.16 Newron Pharmaceuticals Inc.
- 22.16.1 Financial Analysis
- 22.16.2 Product Portfolio
- 22.16.3 Demographic Reach and Achievements
- 22.16.4 Mergers and Acquisitions
- 22.16.5 Certifications
- 23 Schizophrenia Market – Distribution Model (Additional Insight)
- 23.1 Overview
- 23.2 Potential Distributors
- 23.3 Key Parameters for Distribution Partner Assessment
- 24 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
